HKMPF (Hikma Pharmaceuticals) Other Long Term Assets: $445 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKMPF Hikma Pharmaceuticals PLC HKMPF
90 GF Score
Price $22.19
GF Value $27.67
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Hikma Pharmaceuticals Other Long Term Assets?

Hikma Pharmaceuticals HKMPF 90 Other Long Term Assets is $445 Mil as of Jun. 2026. GuruFocus rates HKMPF with a GF Score™ of 90/100 and a GF Value™ of $27.67 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Hikma Pharmaceuticals's other long-term assets for the quarter that ended in Jun. 2026 was $445 Mil.

Hikma Pharmaceuticals's quarterly other long-term assets increased from Jun. 2025 ($407 Mil) to Dec. 2025 ($410 Mil) and increased from Dec. 2025 ($410 Mil) to Jun. 2026 ($445 Mil).

Hikma Pharmaceuticals's annual other long-term assets increased from Dec. 2023 ($339 Mil) to Dec. 2024 ($388 Mil) and increased from Dec. 2024 ($388 Mil) to Dec. 2025 ($410 Mil).

Hikma Pharmaceuticals Other Long Term Assets Historical Data

* Premium members only.

The historical data trend for Hikma Pharmaceuticals's Other Long Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hikma Pharmaceuticals Other Long Term Assets Chart

Hikma Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Long Term Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 240.00 267.00 339.00 388.00 410.00

Hikma Pharmaceuticals Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Other Long Term Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 331.00 388.00 407.00 410.00 445.00
HKMPF
90GF Score
Hikma Pharmaceuticals PLC HKMPF
Other Long Term Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hikma Pharmaceuticals Other Long Term Assets Calculation

GuruFocus lists Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets under the "Total Long-Term Assets" section.

Other Long Term Assets includes following items:
Investment in Properties
Non-current Accounts Receivable
Non-current Note Receivables
Non-current Deferred Assets
Non-current Prepaid Assets
Defined Pension Benefit
Other (too numerous to list)
Some companies can do choose to report each of these items separately. Yet, there are a variety of Other Long Term Assets which are simply too numerous to list.

Frequently Asked Questions Learn more about Other Long Term Assets →
What does a Other Long Term Assets of $445 Mil mean?
Hikma Pharmaceuticals (HKMPF) has a Other Long Term Assets of $445 Mil as of Jun. 2026. Other long-term assets as record on a company's balance sheet not categorized as standard assets. View historical data on Hikma Pharmaceuticals and its competitors.
Is Hikma Pharmaceuticals' Other Long Term Assets too high?
Hikma Pharmaceuticals' current Other Long Term Assets is $445 Mil. Overall, Hikma Pharmaceuticals has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Hikma Pharmaceuticals' Other Long Term Assets compare to ZTS and UTHR?
Hikma Pharmaceuticals' Other Long Term Assets of $445 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long Term Assets for a Drug Manufacturers company?
A good Other Long Term Assets depends on the Drug Manufacturers industry context. However, Other Long Term Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long Term Assets mean?
A high Other Long Term Assets can signal that a stock is expensive relative to its fundamentals. Other long-term assets as record on a company's balance sheet not categorized as standard assets. View historical data on Hikma Pharmaceuticals and its competitors. Hikma Pharmaceuticals's current Other Long Term Assets is $445 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hikma Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Hikma Pharmaceuticals (HKMPF) is currently considered Modestly Undervalued. The stock's GF Value™ is $27.67, compared to a current price of $22.19 — trading 19.8% below its estimated fair value. The current Other Long Term Assets is $445 Mil. Hikma Pharmaceuticals' overall GF Score™ is 90/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long Term Assets calculated?
Other Long Term Assets is calculated from a company's financial statements. For Hikma Pharmaceuticals (HKMPF), the current Other Long Term Assets is $445 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Hikma Pharmaceuticals (HKMPF) Overvalued in 2026?

Based on GuruFocus' analysis, Hikma Pharmaceuticals stock appears to be undervalued. The current stock price of $22.19 is trading 19.8% below its estimated GF Value™ of $27.67. GuruFocus considers Hikma Pharmaceuticals to be Modestly Undervalued.

Key valuation signals for HKMPF:

  • Other Long Term Assets: $445 Mil
  • GF Value™: $27.67 vs. price of $22.19 (19.8% below fair value)
  • GF Score™: 90/100 with 4 warning signs

No single metric tells the full story. See the HKMPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Hikma Pharmaceuticals Business Description

Address 10 Portman Square, London, GBR, W1H 6AZ
Hikma Pharmaceuticals PLC is engaged in developing, manufacturing, and marketing a broad range of generic, branded, and in-licensed pharmaceutical products. The firm operates in three segments: injectables, Rx, and branded. The majority of the company's revenue is generated from its injectables segment, which supplies hospitals across markets with generic injectable products, supported by its manufacturing facilities. Geographically, North America is the company's key revenue-generating market, followed by the Middle East and North Africa, the United Kingdom, Europe, and the rest of the world.
90GF Score

Get the complete analysis for HKMPF

Other Long Term Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$22.19
Price
$27.67
GF Value